Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors

Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors

Abstract Background Immune checkpoint inhibitors (ICI) have become standard treatment in different tumor entities. However, safe treatment with ICI targeting the PD-1/PD-L1 axis requires early detection of immune-related adverse events (irAE). There exist different questionnaires of drug manufacture...

Full description

Bibliographic Details
Main Authors: Luisa Maria Griewing, Claudia Schweizer, Philipp Schubert, Sandra Rutzner, Markus Eckstein, Benjamin Frey, Marlen Haderlein, Thomas Weissmann, Sabine Semrau, Antoniu-Oreste Gostian, Sarina K. Müller, Maximilian Traxdorf, Heinrich Iro, Jian-Guo Zhou, Udo S. Gaipl, Rainer Fietkau, Markus Hecht
Format: Article
Language:English
Published: BMC 2021-03-01
Series:BMC Cancer
Subjects:
Immune checkpoint inhibitors
PD-1
Immune-related adverse events
Toxicity
Questionnaire
PD-L1
Online Access:https://doi.org/10.1186/s12885-021-08006-0

Internet

https://doi.org/10.1186/s12885-021-08006-0

Similar Items